Clinical Trials Logo

Recurrent Prostate Cancer clinical trials

View clinical trials related to Recurrent Prostate Cancer.

Filter by:

NCT ID: NCT00109811 Completed - Clinical trials for Adenocarcinoma of the Prostate

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well vaccine therapy works in treating patients with recurrent prostate cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells

NCT ID: NCT00103337 Completed - Clinical trials for Recurrent Prostate Cancer

Cilengitide in Treating Patients With Metastatic Prostate Cancer

Start date: January 2005
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying how well cilengitide works in treating patients with metastatic prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor

NCT ID: NCT00103194 Completed - Clinical trials for Recurrent Prostate Cancer

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

Start date: September 2005
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lapatinib ditosylate works in treating patients with a rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that prostate cancer has come back after previous treatment. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may delay or prevent the progression of prostate cancer.

NCT ID: NCT00096499 Completed - Clinical trials for Adenocarcinoma of the Prostate

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

Start date: April 2005
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well SB-715992 works in treating patients with metastatic prostate cancer that did not respond to docetaxel or paclitaxel

NCT ID: NCT00095667 Completed - Clinical trials for Recurrent Prostate Cancer

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

Start date: November 2004
Phase: Phase 2
Study type: Interventional

Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent or metastatic prostate cancer.

NCT ID: NCT00089362 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Start date: July 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00087139 Completed - Clinical trials for Adenocarcinoma of the Prostate

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Start date: September 2004
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well ixabepilone works in treating patients with metastatic prostate cancer that has not responded to previous hormone therapy.

NCT ID: NCT00080899 Completed - Clinical trials for Adenocarcinoma of the Prostate

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Start date: June 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00074022 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

Start date: October 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining GTI-2040 with docetaxel in treating patients who have recurrent, metastatic, or unresectable locally advanced non-small cell lung cancer, prostate cancer, or other solid tumors. GTI-2040 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of docetaxel by making the tumor cells more sensitive to the drug. Combining GTI-2040 with docetaxel may kill more tumor cells

NCT ID: NCT00058253 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Start date: February 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as docetaxel and 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.